stockrow
Saturday 7 November 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million.
- EPS
- +25.6%
- Free cash flow
- −39.6%
Quarter to September 2026, against a year earlier
6.57
0.39
+6.31%
Follow SLDB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 14 | 8 | — | — | — | 11 | (40.6%) | 9 | 9 | 84 | +213.3% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | — | — | — | 0.00 | +100.0 pt | ||||||
| EBT | (24) | (53) | (75) | (117) | (88) | (72) | (86) | (96) | (125) | (174) | (215) | +24.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (530.01) | (1,062.28) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (24) | (53) | (75) | (117) | (88) | (72) | (86) | (96) | (125) | (174) | (215) | +24.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.91 | 0.95 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (152.13) | (43.18) | (33.73) | (43.63) | (25.49) | (10.19) | (10.10) | (4.83) | (3.06) | (1.99) | (1.79) | (38.2%) | ||||||
| Cash flow | (177.58) | (47.48) | (31.64) | (34.50) | (16.35) | (10.92) | (11.51) | (4.74) | (2.45) | (1.79) | (1.32) | (40.0%) | ||||||
| Capex | (3.46) | (2.50) | (3.50) | (1.63) | (0.26) | (0.18) | (0.28) | (0.08) | (0.02) | (0.01) | (0.01) | (46.6%) | ||||||
| Free cash flow | (181.04) | (49.98) | (35.15) | (36.13) | (16.61) | (11.10) | (11.79) | (4.81) | (2.47) | (1.80) | (1.33) | (40.1%) | ||||||
| Book value | (334.39) | (65.09) | 56.42 | 29.79 | 38.15 | 29.25 | 24.87 | 6.36 | 3.36 | 2.06 | 2.27 | n/m | ||||||
| Shares, m | 0 | 1 | 2 | 3 | 3 | 7 | 9 | 20 | 41 | 88 | 123 | +109.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 13.72 | 4.25 | — | — | — | 88.22 | 9.0 | ||||||
| P/B | — | — | — | — | — | 0.90 | 0.23 | — | — | — | 2.90 | 0.6 | ||||||
| EV/Sales | — | — | — | — | — | (1.52) | (14.60) | — | — | — | 57.17 | (8.1) | ||||||
| EV/FCF | — | — | — | — | — | 0.26 | 1.64 | — | — | — | (3.21) | 0.9 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (20) | (43) | (70) | (93) | (57) | (78) | (98) | (94) | (100) | (156) | (199) | +25.6% | |||||
| Capex | 0 | (2) | (8) | (4) | (1) | (1) | (2) | (2) | (1) | (1) | (1) | +11.8% | ||||||
| Free cash flow | (21) | (45) | (78) | (97) | (57) | (79) | (100) | (96) | (101) | (157) | (200) | +25.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 33 | 59 | 116 | 68 | 134 | 199 | 197 | 115 | 127 | 172 | 335 | +20.1% | |||||
| Net debt | (38) | (69) | (122) | (83) | (154) | (207) | (212) | (122) | (149) | (189) | (350) | +19.6% | ||||||
| Shareholders’ equity | (38) | (59) | 125 | 80 | 132 | 208 | 212 | 126 | 137 | 180 | 342 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (35.77) | (67.31) | (69.32) | (96.45) | (64.30) | (35.78) | (34.91) | (45.16) | (70.53) | (82.78) | (64.86) | (47.0) pt | |||||
| ROIC | 0.00 | 0.00 | (1,322.09) | 0.00 | 0.00 | (6,228.79) | 0.00 | (1,598.96) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 59.61 | 80.95 | (226.92) | (114.24) | (83.24) | (42.43) | (40.96) | (56.79) | (94.57) | (109.90) | (76.87) | (169.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 60 | 60 | 111 | 121 | 70 | 104 | 87 | 88 | 100 | 121 | — | +8.1% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.09 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Dec 2022 · fundamentals updated 6 Nov 2026
Solid Biosciences Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SANA Sana Biotechnology, Inc. | $700.5M | — (loss-making) | — | — | n/m | −5.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGEM Cullinan Therapeutics, Inc. | $695.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ATTO Attovia Therapeutics, Inc. | $684.8M | — | — | — | n/m | — | 100.00% | (4,845.11%) | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $670.7M | — (loss-making) | — (loss-making) | −59.37% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| SLDB Solid Biosciences Inc. | $662.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACHV Achieve Life Sciences, Inc. | $656.0M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SGMT Sagimet Biosciences Inc. | $641.5M | — (loss-making) | — (loss-making) | — | n/m | −21.95% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| WVE WAVE Life Sciences Ltd. | $635.1M | — (loss-making) | — (loss-making) | +72.95% (above 0%: growing) | n/m | −33.94% (below 0%: shrinking) | 100.00% | (501.95%) | Compare |
| Median of peers | $664.1M | — | — | +54.44% | — | −19.01% | 95.73% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 5.22m | 7.79m | 104.83 |
| 2024 | 4.87m | 3.45m | 74.35 |
| 2023 | 918.63k | 862.41k | 114.13 |
Ownership
Directors and executive officers, together
2.66%
Perceptive Life Sciences Master Fund, Ltd. and affiliated entities
12.16%
Entities affiliated with Bain Capital Life Sciences Investors, LLC
9.99%
Invus Public Equities, L.P. and affiliated entities
9.99%
Entities affiliated with RA Capital Management, L.P.
9.99%
Entities associated with Vestal Point Capital, LP
9.36%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement